Tamaño del mercado de células madre que se alcanzará $15.63 mil millones por 2025 | CAGR: 9.2%

Se espera que el mercado mundial de células madre alcance los 15.630 millones de dólares en 2025, creciendo a una CAGR de 9.2%, según un nuevo informe de Grand View Research, Cª. Augmentation in research studies that aim at broadening the utility scope of associated products is anticipated to drive the market growth. These research projects have opened the possibility of implementation of several clinical applications of these cells, thereby impacting disease-modifying treatments.

Scientists are engaged in discovering novel methods to create human stem cells. This is to address the increasing demand for stem cell production for potential investigation in disease management. This factor is certainly expected to accelerate the development of regenerative medicine, thus driving industrial growth.

Además, cellular therapies are recognized as the next major advancements in transforming healthcare. Firms are expanding their cellular therapy portfolio, understanding the future potential of this arena in the treatment of Parkinson’s disease, tipo 1 diabetes, lesión de la médula espinal, enfermedad de alzheimer, y otros.

In March 2016, Scientists at Michigan State University unveiled new kind of cells “induced XEN cells” from a cellular trash pile. This discovery is expected to drive advancements in regenerative medicine. Such discoveries are anticipated to bolster research and sales in this market over the forecast period.

 

Further key findings from the report suggest:

Células madre adultas

dominated the market and is expected to maintain its dominance. This can be attributed to the several factors such as lower rejection rates, long term renewal property, and no ethical concerns associated with their usage

Application wise regenerative medicine is estimated to hold the substantial share of the revenue

Presence of significant number pipeline projects for regenerative medicine is expected to fuel growth in the market

Además, exploding research projects have driven the need of harvesting techniques, thereby propelling progress of acquisition technology

Increased R&D activities and huge funds granted by funding bodies to advance cellular research in the U.S. have resulted into the large share of North America

Extensive research carried out in Singapore and Japan is anticipated to drive progress with lucrative avenues

Advanced Cell Technology Inc, Osiris Therapeutics Inc, Celgene Corporation, BIOTIME, INC., Cynata, and STEMCELL Technologies Inc., are some of the major companies operating in this market

A number of stem cells companies

are engaged in seeking investment from overseas organizations and also developing partnerships with the pharmaceutical organizations

Grand View Research has segmented the global stem cells market on the basis of product, application, tecnología, terapia, and region:

Stem Cell Product Outlook (Ganancia, USD Billion, 2014 – 2025)

Células madre adultas

Células madre neuronales

Células madre hematopoyéticas

Células madre mesenquimales

Células madre del cordón umbilical

Otros

Human Embryonic Stem Cells

Células madre pluripotentes inducidas

Very Small Embryonic Like Stem Cells

Stem Cell Application Outlook (Ganancia, USD Billion, 2014 – 2025)

Medicina Regenerativa

Neurología

Ortopedía

Oncología

Hematology

Cardiovascular and Myocardial Infraction

Lesiones

Diabetes

Liver Disorder

Incontinence

Otros

Descubrimiento y desarrollo de fármacos

Stem Cell Technology Outlook (Ganancia, USD Billion, 2014 – 2025)

Cell Acquisition

Bone Marrow Harvest

Umbilical Blood Cord

Aféresis

Cell Production

Clonación terapéutica

In-vitro Fertilization

Cell Culture

Aislamiento

criopreservación

Expansion and Sub-Culture

Stem Cell Therapy Outlook (Ganancia, USD Billion, 2014 – 2025)

Terapia con células madre autólogas

Terapia alogénica con células madre

 

To request this report, please contact Dr Eugene Zadorin

( [email protected] )